We have a seasoned management team that brought 30+ innovative therapeutic agents from early-phase development to the global market. Our team possesses deep scientific, clinical, regulatory and operational expertise in both the U.S. and China, which optimally positions BeyondSpring to accomplish its near- and long-term objectives.
Lan Huang, Ph.D.
Co-founder, Chairman & CEO
Dr. Huang has more than a decade of entrepreneurial experience in the Chinese and U.S. biotechnology industry. She has invented and holds patents for a number of biotech products for oncology and dermatology indications. In 2009, she was the recipient of China’s “Thousand Talent Innovator Award.”
Prior to founding BeyondSpring, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., whose self-designed cancer peptide drug’s China rights were acquired in 2010 by Shanghai Pharmaceutical Group, one of the top three pharmaceutical companies in China. She also co-founded Paramax International, a clinical CRO company in China, which was sold to RPS (a global CRO), then to Warburg Pincus in 2011. In addition, Dr. Huang worked with Forward Ventures, where she led partnering initiatives between Forward’s portfolio companies and Chinese pharmaceutical companies.
Dr. Huang was trained at Memorial Sloan Kettering Cancer Center, where her breakthrough research in solving the first E2-E3 ubiquitin ligase structure involving P53 degradation was published in Science following 10 months of preparation. The immense importance of this field is illustrated by the 2005 award of the Nobel Prize in Chemistry to the founders of ubiquitin-mediated protein degradation. She received her Ph.D. in Chemistry in four-and-a-half years from the University of California at Berkeley, where she won the graduating Ph.D. woman award from Soroptimist International. Her translational research in cancer signaling pathways involving Ras was published in two Nature papers.
Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee. She also studied at Fudan University in Shanghai, China.
Ramon Mohanlal, M.D., Ph.D., M.B.A.
Executive Vice President and Chief Medical Officer
Head of Business Development
Dr. Mohanlal has more than 20 years of global experience in strategic drug development at big pharma, and biotech start-ups, including GlaxoWellcome (GSK), Pharmacia (Pfizer), Vertex, Interleukin Genetics, Syntium, Novartis, and AstraZeneca. His expertise includes drug development in all Phases (preclinical and 1, 2, 3, 4 clinical, post-marketing), regulatory filings and maintaining drugs on the market. Dr. Mohanlal played a crucial role in bringing five drugs to market and was deeply involved in the development of 15 marketed drugs, including Wellferon, Atovaquone, Lamuvidine, Zomig, Advexin, Abilify IM Depot, Zometa, Femara, Aredia, Proleukin, Cardioxane and Exjade. Most recently, Dr. Mohanlal was the Clinical Head of Established Oncology Products for Novartis, where he managed all clinical and regulatory maintenance work for the division, which represented total annual revenue of approximately $2 billion. He also developed immuno-oncology development programs based on checkpoint inhibitor combination therapy at AstraZeneca. Prior to this, Dr. Mohanlal held positions with Interleukin Genetics as Chief Medical Officer and Vertex Pharmaceuticals as Medical Director. Dr. Mohanlal has also obtained extensive licensing and deal-making experience at Syntium Inc. Dr. Mohanlal earned his M.D. and Ph.D. in Experimental CV Pharmacology, both from the University of Leiden, The Netherlands, as well as his M.B.A. from the American Intercontinental University in Illinois, with post-graduate business training at the MIT Sloan School of Management, Cambridge, Massachusetts.
Richard A. Brand, M.B.A.
Chief Financial Officer
Mr. Brand has two decades of experience as an investment banking and capital markets professional, as well as a dozen years of experience in institutional investment management. He was Head of Robertson Stephens’ Private Capital Markets Group when its biotech practice was ranked No. 2 in the industry. He raised VC/PE firms’ equity capital as the first broker to obtain such allocations from public pension plans, as a member of the No. 1-ranked team at Merrill Lynch and as a founder of the same business at DLJ that quickly also became No 1. Earlier, Mr. Brand originated and managed Merrill Lynch’s first $1 billion deal. In addition to his capital markets experience, Mr. Brand performed external CFO duties for a newly public company as it grew 101 percent per annum to its current size of more than $6 billion in assets. He is on the board of the University of Chicago’s New York City Alumni Association and holds an M.B.A. from the University’s Booth School of Business. Mr. Brand received a B.A. from the University of Iowa, where he was Vice President of the Council of Academic Colleges after turning around the used book sale business and successfully starting another business.
G. Kenneth Lloyd, Ph.D.
Chief Scientific Officer
Dr. Lloyd has more than 45 years of experience in the pharmaceutical industry, with a focus on novel drug discovery and development, working in both large pharma (F. Hoffman LaRoche, Synthelabo and Wyeth Ayerst) and start-up biotechs (SIBIA, Nereus). Previous positions include Vice-Director at Synthelabo (now Sanofi), Director of Research at Wyeth U.K. and Chief Scientific Officer at Nereus Pharmaceuticals, where he was responsible for the discovery, selection and development of Plinabulin. In addition to Plinabulin, Dr. Lloyd has led the development of marizomib (proteasome inhibitor for multiple myeloma), progabide and the discovery and early development of zolpidem. Dr. Lloyd received his undergraduate education and M.S. in Biochemistry at McGill University and Ph.D. in Pharmacology and Toxicology from the University of Toronto, followed by a post-doctoral fellowship at F. Hoffmann LaRoche in Basel. He has more than 300 publications in journals that include Science, Nature and the New England Journal of Medicine.
Gordon L. Schooley, Ph.D.
Chief Regulatory Officer
Dr. Schooley has 35 years of experience in the pharmaceutical industry, with a focus on clinical and regulatory affairs, and he has been associated with product development and approvals of 19 marketed drugs in the U.S., Europe and Pacific Rim countries. Previous positions include Director of Clinical Research at Allergan, V.P. of Clinical Research & Regulatory Affairs at Newport Pharmaceuticals International, V.P. of Clinical Research & Regulatory Affairs at Alliance Pharmaceutical Corp. and CSO and Senior V.P. of Clinical Development & Regulatory Affairs at Skye Pharma-Pacira Pharmaceuticals. He has participated in multiple product approvals in the U.S., Canada, Australia and Europe, including those for DepoCyte, 5-flurouracil, Solarize and Alprazolam. He also has experience in oncology, including hepatic carcinoma, neoplastic meningitis and glioblastoma. Dr. Schooley received his undergraduate training and M.S. at Brigham Young University and Ph.D. in Biostatistics and Medical Care Organization & Administration at the University of Michigan, School of Public Health.